Silverarc Capital Management LLC Has $6.63 Million Stock Position in Biodesix, Inc. (NASDAQ:BDSX)

Silverarc Capital Management LLC boosted its stake in Biodesix, Inc. (NASDAQ:BDSX - Free Report) by 21.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,332,281 shares of the company's stock after purchasing an additional 771,187 shares during the quarter. Biodesix comprises 1.4% of Silverarc Capital Management LLC's investment portfolio, making the stock its 26th biggest position. Silverarc Capital Management LLC owned 2.98% of Biodesix worth $6,628,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Susquehanna International Group LLP lifted its holdings in shares of Biodesix by 769.8% during the 4th quarter. Susquehanna International Group LLP now owns 1,115,748 shares of the company's stock worth $1,707,000 after acquiring an additional 987,475 shares during the period. MYDA Advisors LLC bought a new position in shares of Biodesix in the 4th quarter valued at $76,000. Barclays PLC raised its holdings in shares of Biodesix by 387.3% during the 4th quarter. Barclays PLC now owns 112,254 shares of the company's stock worth $171,000 after buying an additional 89,218 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Biodesix by 775.2% during the 4th quarter. Renaissance Technologies LLC now owns 360,200 shares of the company's stock worth $551,000 after buying an additional 319,043 shares during the last quarter. Finally, Samjo Management LLC acquired a new stake in Biodesix in the fourth quarter valued at about $3,790,000. Institutional investors own 20.96% of the company's stock.

Biodesix Trading Down 8.9 %

Shares of NASDAQ BDSX opened at $0.50 on Tuesday. The stock has a market cap of $72.99 million, a P/E ratio of -1.28 and a beta of 1.17. The firm has a 50 day moving average price of $0.73 and a two-hundred day moving average price of $1.14. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40. Biodesix, Inc. has a 52-week low of $0.48 and a 52-week high of $2.04.

Biodesix (NASDAQ:BDSX - Get Free Report) last announced its earnings results on Monday, March 3rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. The business had revenue of $20.43 million during the quarter, compared to analyst estimates of $19.92 million. As a group, equities analysts forecast that Biodesix, Inc. will post -0.35 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, William Blair reissued an "outperform" rating on shares of Biodesix in a report on Tuesday, March 4th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Biodesix presently has an average rating of "Buy" and an average target price of $2.95.

Insider Buying and Selling at Biodesix

In other news, CEO Scott Hutton sold 83,660 shares of the stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total transaction of $76,967.20. Following the completion of the sale, the chief executive officer now directly owns 701,947 shares in the company, valued at $645,791.24. This represents a 10.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders sold 128,702 shares of company stock valued at $118,406. 69.20% of the stock is currently owned by company insiders.

Biodesix Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

Want to see what other hedge funds are holding BDSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biodesix, Inc. (NASDAQ:BDSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.